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Dipeptidyl peptidase (DPP)-4 inhibitors are approved for use in monotherapy or in com-
bination therapy for patients with type 2 diabetes mellitus for <1 decade. However,
numerous reports of DPP-4 inhibitors induced acute pancreatitis were made through the
US Food and Drug Administration Adverse Event Reporting System, and this led to a
revision in the prescribing information for these drugs. Therefore, this study is designed to
evaluate DPP-4 inhibitors induced acute pancreatitis via the spontaneous adverse drug
reactions (ADRs) reporting system in a medical center. In four of 2305 ADR cases, it is
suspected that DPP-4 inhibitors induced moderate to serious acute pancreatitis. Beyond
drugs, other factors also contribute to acute pancreatitis and affect the possibility of ADRs
assessed using the Naranjo algorithm. Finally, our results indicate that the incidence of
DPP-4 inhibitors induced acute pancreatitis is low.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic, progressive
illness that requires continuing medical care to prevent acute
complications and to reduce the risk of long-term complica-
tions, particularly cardiovascular events [1]. According to theuan 1st Road, Sanmin D
(C.-Y. Chen).
inistration, Taiwan. Publis
/licenses/by-nc-nd/3.0/).recommendations of the American Diabetes Association and
the European Association for the Study of Diabetes, the main
therapeutic goal in T2DM is the achievement and mainte-
nance of glycemic levels as close to the nondiabetic range as
possible [glycosylated hemoglobin (HbA1C) < 7.0%] [2].Tradi-
tional antihyperglycemic drugs include insulin and insulin
analogues, insulin sensitizers (metformin andistrict, Kaohsiung City 80708, Taiwan, ROC.
hed by Elsevier Taiwan LLC. This is an open access article under the CC
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glinides), and agents that inhibit dietary carbohydrate break-
down (a-glucosidase inhibitors) [3]. Novel antidiabetic drugs,
developed on the basis of an improved understanding of the
mechanisms that govern glucose homeostasis, include the
incretin-based agents, namely, glucagon-like peptide (GLP)-1
receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors
(also named “gliptins”). These drugs enhance glucose-
dependent insulin secretion from pancreatic b cells and
glucose-dependent suppression of glucagon release from
pancreatic a cells, respectively, by mimicking the glucor-
egulatory effects of endogenous GLP-1 (GLP-1 receptor ago-
nists or incretin mimetics) or enhancing endogenous GLP-1
concentrations (DPP-4 inhibitors or incretin enhancers) [4].
DPP-4 inhibitors, such as sitagliptin and vildagliptin with
metformin, have been approved for use in monotherapy or in
combination therapy for patients with type 2 diabetes since
2006 [5]. A large body of evidence indicates that DPP-4 in-
hibitors as a class have a good safety and tolerability profile,
with a low incidence of mostly mild to moderate adverse
events. However, numerous reports of DPP-4 inhibitors
induced acute pancreatitis were made through the US Food
and Drug Administration Adverse Event Reporting System,
and it led to a revision in the prescribing information for these
drugs [6]. Therefore, this study is designed to evaluate DPP-4
inhibitors induced acute pancreatitis via the spontaneous
adverse drug reaction (ADR) reporting system in a medical
center.2. Case Report
ADR cases of DPP-4 inhibitors induced acute pancreatitis in
our hospital, which had been reported to the National
Reporting Center of Adverse Drug Reaction during January
2009 to December 2014, were collected, and the severity was
analyzed using descriptive statistics. Moreover, the prescrip-
tion amounts of suspected gliptins, sitagliptin, and vilda-
gliptin with metformin, are analyzed to understand the
incidence of DPP-4 inhibitors induced acute pancreatitis in the
same period. A total of 2305 ADR cases were reported to the
National Reporting Center of Adverse Drug Reaction between
January 2009 and December 2014, including reports that four
of regular follow-up type 2 diabetic patients had come to our
emergency department for help with a discharge diagnosis of
acute pancreatitis induced suspiciously by gliptins during theTable 1eCharacteristics of reporting cases during 2009 to
2014.
Item No. (%)
Case number (total) 2305 100
ADR of DPP-4 inhibitors induced acute pancreatitis 4 0.17
Severity of DPP-4 inhibitors induced acute pancreatitis
Mild 0 0.00
Moderate 3 0.23
Serious 1 1.35
ADR ¼ adverse drug reaction; DPP-4 inhibitors ¼ dipeptidyl pepti-
dase-4 inhibitors.same period (Table 1). Because the average length of hospital
stay for a patient with acute pancreatitis is approximately 5e6
days [7], one case (Patient 3) was defined as serious ADR
because hospitalization lasted more than 7 days until recov-
ery. The other three cases (Patients 1, 2, and 4) were defined as
moderate because hospitalization lasted only 2e5 days. After
withholding gliptins, medical intervention, nothing by mouth
combined with adequate intravenous fluid supply, and
medication for symptom relief, all patients achieved clinical
recovery (Tables 1 and 2).
Moreover, the initial data of the four cases, including un-
derlying diseases as defined by International Classification of
Disease, Ninth edition, Clinical Modification (ICD-9-CM) codes,
suspected gliptins, concurrent hypoglycemic agents, HbA1C,
duration of gliptins treatment, clinical manifestations,
gastrointestinal outcomes, other risk factors, and the Naranjo
scale [8], were presented (Table 2). The underlying diseases
included T2DM with or without renal or neurological mani-
festations (ICD-9-CM codes: 250.00, 250.40, 250.60), malignant
neoplasm of the thyroid gland (ICD-9-CM codes: 193), hyper-
lipidemia (ICD-9-CM codes: 272.4), hypercholesterolemia (ICD-
9-CM codes: 272.0), hypertension (ICD-9-CM codes: 401.1,
401.9), constipation (ICD-9-CM codes: 564.0), transient disor-
der of initiating ormaintaining sleep (ICD-9-CM codes: 307.41),
and hepatitis (ICD-9-CM codes: 573.3). Suspected gliptins were
sitagliptin and vildagliptin with metformin. Concurrent hy-
poglycemic agents were glimepiride, gliclazide, pioglitazone,
and insulin. The four patients had been treated by sitagliptin
(for 699e1455 days), and three had been further treated by
vildagliptin with metformin (for 27e276 days). Before the first
dose of gliptins was taken, the level of HbA1C was more than
7% in three cases and one patient’s level was equal to 7%.
When Patient 3 stopped taking all gliptins, the level of HbA1C
was < 7%. Clinical manifestations included abdominal pain
(100%), abnormal serum amylase level (100%), abnormal
serum lipase level (75%), and computed tomography-proven
pancreas lesions (75%). Other risk factors were smoking
(50%), alcohol consumption (25%), and obesity (50%). Applying
the Naranjo scale, three reports were classified as possible
(75%) and one as probable (25%).
By contrast, sitagliptin was prescribed 139,706 times, and
the combination product, vildagliptin with metformin, was
prescribed 20,631 times in our diabetic outpatient setting at
the same time. The incidence of DPP-4 inhibitors induced
acute pancreatitis is rare in our hospital during the past 5
years, accounting for approximately < 0.1%.3. Discussion
Acute pancreatitis is an inflammatory condition of the
pancreas characterized clinically by abdominal pain and
elevated levels of pancreatic enzymes in the blood [9]. The
pathogenesis of acute pancreatitis is not fully understood.
Pancreatitis due to medications is rare (0.3e1.4%), although
limited data suggest that the incidence may be increasing.
Several medications have been associated with drug-induced
pancreatitis, and a number of different mechanisms of drug-
induced pancreatitis have been proposed [7]. These mecha-
nisms include immunologic reactions, direct toxic effect,
Table 2 e Demographic data, clinical characteristics, and outcome of four suspicious gliptins induced acute pancreatitis patients.
Severity Age
(y)/sex
Underlying
disorders (by
ICD-9 codes)
Suspected
gliptins
Duration of
gliptins
treatment (d)
Concurrent
hypoglycemic
agents
HbA1C (4e6%) Clinical
manifestations
Gastrointestinal
outcome after
gliptins were
discontinued
Other risk factors Naranjo
ScaleBefore
the first
dose of
gliptins
used
When all
gliptins
were
suspended
Smoking Alcohol
consumption
Obesity
(BMI)
Moderate 60/F 193: malignant
neoplasm of
thyroid gland
272.4:
hyperlipidemia
250.00: type
2 diabetes
mellitus
401.1:
hypertension
Sitagliptin Sitagliptin:
699
Glimepiride 7.4 7.8 Abdominal pain Nonavailable Nonavailable BWa: 70 kg 3
Metformin Amylase: 163 U/L
(basal: nonavailable)
Amylase: 63 U/L
Lipase: 253 U/L
(basal: nonavailable)
Lipase: 29 U/L
CT-proven Grade
A, B pancreatitis
Moderate 53/F 250.40: type 2
diabetes mellitus
with renal
manifestations
Vildagliptin
with metformin
(status post
sitagliptin used)
Sitagliptin:
1445
Gliclazide 13.1 9.8 Abdominal pain No No Yes (26.9) 4
250.60: type 2
diabetes mellitus
with neurological
manifestations
401.9: hypertension
Vildagliptin:
27
Insulin Amylase: 294 U/L
(basal: 16 U/L)
Amylase: 66 U/L
272.4: hyperlipidemia
307.41: transient
disorder
of initiating or
maintaining sleep
Lipase: 18 U/L
(basal: 13 U/L)
Lipase: 36 U/L
Serious 68/M 250.00: type 2
diabetes mellitus
Vildagliptin
with metformin
(status post
sitagliptin used)
Sitagliptin:
980
Gliclazide 7.0 6.9 Abdominal pain Yes Yes No (21.2) 5
272.0: hyperlipidemia Vildagliptin:
57
Pioglitazone Amylase: 379 U/L
(basal: nonavailable)
Amylase: 232 U/L
Lipase: 684 U/L
(basal: nonavailable)
Lipase: 312 U/L
CT-proven Grade
B pancreatitis
Autoimmune
pancreatitis was
suspected during
further clinic visit
Moderate 63/M 250.00: type 2
diabetes mellitus
250.60: type 2
diabetes mellitus
with neurological
manifestations
573.3: hepatitis
272.0 hyperlipidemia
564.0: constipation
Vildagliptin
with metformin
(status post
sitagliptin used)
Sitagliptin:
1355
Insulin 8.3 10.3 Abdominal pain Yes No Yes (28.4) 4
Vildagliptin:
276
Amylase: 1550 U/L
(basal: nonavailable)
Amylase: 62 U/L
Lipase: 1698 U/L
(basal: nonavailable)
Lipase: 50 U/L
CT-proven groove
pancreatitis
BMI ¼ body mass index; BW ¼ body weight; CT ¼ computed tomography; HbA1C ¼ glycosylated hemoglobin; ICD-9 ¼ International Classification of Disease, Ninth edition, Clinical Modification.
a Only body weight available.
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thrombosis, and an increased viscosity of pancreatic juice.
Acute pancreatitis has been reported in association with DPP-
4 inhibitors treatment. However, there are insufficient data to
determine if there is a causal relationship at present. In
addition, a population-based study on a Taiwanese popula-
tion had revealed that the risk of acute pancreatitis was not
significantly higher among DPP-4 inhibitor users compared
with nonusers [10]. Although our study is a simple descriptive
one that did not involve a comparison group, it is noteworthy
that the incidence, accounting for 0.17% of 5-year ADR
reporting data, of DPP-4 inhibitors induced acute pancreatitis
is rare in our study.
Second, other factorsmay also include the etiology of acute
pancreatitis beyond drugs [7]. The approach to determine the
etiology of acute pancreatitis are the following: previous
symptoms or documentation of gallstones, alcohol use, his-
tory of hypertriglyceridemia or hypercalcemia, family history
of pancreatic disease, prescription and nonprescription drug
history, history of trauma, and the presence of concomitant
autoimmune diseases. Aside from T2DM, some of our cases
had dyslipidemia, some had liver problems, and some were
smokers or alcohol users, which may also contribute to acute
pancreatitis. These factors are known to affect the possibility
of ADRs as assessed by the Naranjo algorithm.
Third, there is no study concluding how long it takes for
acute pancreatitis to occur after patients had started taking
DPP-4 inhibitors. Intriguingly, even though the underlying
conditions and other risk factors varied among patients, all
our patients had been taking gliptins for more than 1 year
(long term), and all had initial manifestations of accidental
abdominal pain with abnormal serum amylase level. There-
fore, pancreatitis should be considered in patients with
persistent severe abdominal pain (with or without nausea),
and DPP-4 inhibitors should be discontinued in such patients,
even if they had been in use for a long time. If pancreatitis is
confirmed, a DPP-4 inhibitor should not be restarted. In
addition, DPP-4 inhibitors should not be initiated in patients
with a history of pancreatitis. Furthermore, although further
well-conducted studies are needed to prove it, female and
elderly DPP-4 inhibitor users had significantly elevated risks of
acute pancreatitis development [10]. Our study cannot reflect
that sex and age are risk factors for DPP-4 inhibitors users to
develop acute pancreatitis, but physicians may pay more
attention to these groups.4. Conclusion
From our results, the incidence of DPP-4 inhibitors induced
acute pancreatitis in patients with T2DM is rare. Althoughphysicians should remain attentive for this rare but potential
complication, DPP-4 inhibitors are still reasonable options for
type 2 diabetic patients who are being monitored for adverse
symptoms. Otherwise, because pancreatitis could happen any
time during care, patients and their caregivers should be on
alert for signs of pancreatitis including severe stomach pain,
back pain, very upset stomach, or throwing up. DPP-4 in-
hibitors should also be discontinued in such patients to pre-
vent irreversible pancreatic harm.Conflicts of interest
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